mTOR pathway activation is a favorable prognostic factor in human prostate adenocarcinoma.

Prostate cancer patients with localized disease are treated with curative intent. However, the disease will recur in approximately 30% of patients with a high incidence of morbidity and mortality. Prognostic biomarkers are needed to identify patients with high risk of relapse.

mTOR pathway activation is reported in prostate cancer, but clinical trials testing efficacy of mTOR inhibitors were unsuccessful. To explain this clinical observation, we studied the expression and prognostic impact of mTOR-S2448 phosphorylation in localized prostate carcinomas. mTOR-S2448 phosphorylation is indicative for an activated mTOR pathway in prostate cancer. Surprisingly, the mTOR signaling pathway is activated specifically in prostate cancer patients with a favorable outcome. Since tumors from poor-outcome patients have low levels of mTOR-S2448 phosphorylation, this may explain why mTOR inhibitors proved unsuccessful in prostate cancer trials.

Oncotarget. 2016 Apr 16 [Epub ahead of print]

Suzan Stelloo, Joyce Sanders, Ekaterina Nevedomskaya, Jeroen de Jong, Dennis Peters, Geert Jlh van Leenders, Guido Jenster, Andries M Bergman, Wilbert Zwart

Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Division of Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Division of Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Department of Pathology, Josephine Nefkens Institute, Erasmus Medical Center, Rotterdam, The Netherlands., Department of Urology, Josephine Nefkens Institute, Erasmus Medical Center, Rotterdam, The Netherlands., Division of Medical Oncology, the Netherlands Cancer Institute, Amsterdam, The Netherlands., Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.